by Plasmid DNA is a double-stranded circular DNA molecule that is used as a vector to introduce foreign DNA into a host cell or organism. Plasmid DNA manufacturing involves creating plasmids through bacterial fermentation and plasmid extraction. The rising demand for plasmid DNA in gene and cell therapy development and production is driving the growth of the plasmid DNA manufacturing market.
The global plasmid DNA manufacturing market is estimated to be valued at US$ 1,038.19 million in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period of 2024 to 2031.
Key Takeaways
Key players operating in the plasmid DNA manufacturing market are Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, Waisman Biomanufacturing.
The key opportunities in the Plasmid DNA Manufacturing Market Demand include increasing R&D spending for gene therapies and vaccines. Additionally, growth in outsourcing of plasmid DNA manufacturing to contract service providers is expected to augment the market growth. Technological advancements such as automation, use of disposable equipment and plasmid DNA purification technologies are increasing efficiency and yields in manufacturing.
Market Drivers
The increasing R&D investments, clinical research and demand from gene therapy companies for plasmid DNA are expected to drive the growth of the plasmid DNA manufacturing market. The rising incidence of cancer and other infectious diseases is fueling the development of new gene and cell therapies which require plasmid DNA during development and production stages. Additionally, the increasing government funding and regulatory approvals for gene therapies will propel the demand.
Current Challenges in Plasmid DNA Manufacturing Market
The Plasmid DNA Manufacturing Market faces various challenges which include stringent regulatory norms, high cost involved in the plasmid DNA production, and requirement of skilled labours and professionals for carrying out the complex manufacturing procedures. Compliance to regulations at each stage poses extra cost which cascades down to the product cost. Producing high quality and high yield plasmids via fermentation and purification techniques requires experienced personnel as well as monitoring at each process level to prevent contamination. These factors collectively increase the production cost and make plasmid DNA a relatively expensive product. Additionally, inconsistent scalability during manufacturing hampers cost-effective production of large volumes of plasmid DNA. These challenges pose barrier to the growth prospects of the market to some extent.
SWOT Analysis
Strength: Established manufacturing infrastructure and expertise in contract manufacturing organizations like Cobra Biologics and Charles River Laboratories. Growing R&D investments by companies in cell and gene therapy development.
Weakness: High costs associated with production of plasmids due to stringent regulatory requirements and complex manufacturing process.
Opportunity: Rising research in gene therapy, DNA vaccines, and immunotherapy creates demand for GMP-grade plasmid DNA. Growing outsourcing of manufacturing functions by biotech and pharma companies.
Threats: Presence of alternative technologies like mRNA, viral vectors that can be used for therapeutic development. Stringent regulatory approval process delays product availability.
Geographical Regions
North America region currently holds the major share of plasmid DNA manufacturing market in terms of value. This is attributed to large presence of biotech and pharma companies conducting research activities in cell and gene therapies. United States also has robust biosimilars market which drives the plasmid demand. Asia Pacific region is expected to witness fastest growth during the forecast period owing to growing initiatives in research studies, set up of manufacturing facilities, and low production cost in major economies like China and India.
The Europe region is also among the prominent markets for plasmid DNA manufacturing. Countries like Germany, United Kingdom have strong pharmaceutical industry with presence of both global and domestic players focusing on advanced therapies like CAR T-cell therapy. This creates opportunities for plasmid DNA manufacturing companies in the region.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it.
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc.
